title: Elotuzumab for the treatment of multiple myeloma.
abstract: Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.
authors.affiliation: Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
authors.forename: Yucai
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
authors.forename: Larysa
authors.initials: L
authors.lastname: Sanchez
authors.affiliation: Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
authors.forename: David S
authors.initials: DS
authors.lastname: Siegel
authors.affiliation: Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX, 77030, USA. miwang@mdanderson.org.
authors.forename: Michael L
authors.initials: ML
authors.lastname: Wang
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002450:Cell Communication / Q000187:drug effects; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D000071176:Signaling Lymphocytic Activation Molecule Family / Q000037:antagonists & inhibitors; D017154:Stromal Cells / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C448987:SLAMF7 protein, human; D000071176:Signaling Lymphocytic Activation Molecule Family; C546027:elotuzumab